Disse E, Aron-Wisnewsky J, Jacobi D, Clement K, et al. Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data. Diabetes Metab 2025 Feb 17:101625. doi: 10.1016/j.diabet.2025.101625.
PMID: 39971183